RESUMEN
Measles vaccination via the aerosol route has proven effective under field conditions, using vaccine reconstituted prior to nebulization. Inhalation of a dry powder aerosol vaccine would have additional benefits, including easier logistics of administration, reduced cold chain dependence and the potential of single dose administration. We have evaluated two candidate dry powder measles vaccine formulations in macaques. Specific immune responses were demonstrated, but levels of immunity were lower than in animals vaccinated by injection or by nebulized aerosol. These studies provide proof of principle that dry powder inhalation is a possible route for measles vaccination, but suggest that either the vaccine formulation or the method of delivery need to be improved for a better immune response.
Asunto(s)
Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/uso terapéutico , Administración por Inhalación , Anestesia Endotraqueal , Animales , Anticuerpos Antivirales/análisis , Anticuerpos Antivirales/biosíntesis , Inyecciones , Pulmón/metabolismo , Macaca fascicularis , Sarampión/inmunología , Sarampión/prevención & control , Virus del Sarampión/química , Pruebas de Neutralización , Tamaño de la Partícula , Polvos , ARN Viral/análisis , ARN Viral/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Vacunación/métodos , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/uso terapéuticoRESUMEN
The comparative efficacy and safety of measles vaccination via the aerosol route versus subcutaneous injection has not been fully resolved. We vaccinated cynomolgus monkeys (Macaca fascicularis) with the live-attenuated Edmonston-Zagreb measles virus (MV) vaccine and compared different routes of administration in the immunocompetent and the immunocompromised host. Immunogenicity and protective efficacy of aerosol vaccination using devices similar to those previously used in humans were comparable to those in animals vaccinated by injection. No evidence for a safety hazard associated with the route of vaccination was detected. The results of this study support further clinical evaluation of aerosol vaccination for measles.
Asunto(s)
Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/inmunología , Aerosoles/administración & dosificación , Animales , Formación de Anticuerpos/inmunología , Células Cultivadas , Relación Dosis-Respuesta Inmunológica , Evaluación Preclínica de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Huésped Inmunocomprometido/inmunología , Macaca , Masculino , Sarampión/inmunología , Sarampión/virología , Vacuna Antisarampión/efectos adversos , Virus del Sarampión/fisiología , Replicación ViralRESUMEN
Although the currently used live attenuated measles vaccines are safe and effective, they are dependent on cold chain maintenance and are often ineffective in young infants due to interference by maternal antibody. Therefore, besides vector-based vaccines, different new generation non-replicating candidate measles vaccines are being considered, including nucleic acid vaccines. We have vaccinated cynomolgus macaques transdermally with DNA plasmids encoding measles virus (MV) proteins. Following two vaccinations, low serum antibody responses were detected. Wild-type measles virus challenge 1 year after vaccination showed reduced viraemia in some animals. However, accelerated humoral- and cellular-immune responses were observed in all vaccinated macaques, demonstrating successful priming by the DNA vaccines.
Asunto(s)
Anticuerpos Antivirales/sangre , Interferón gamma/biosíntesis , Vacuna Antisarampión/inmunología , Vacunas de ADN/inmunología , Animales , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Macaca fascicularis , VacunaciónRESUMEN
To test the option of oral vaccination with a live attenuated measles vaccine (LAV), we have evaluated the potential of an orally administered enteric-coated tablet containing a candidate LAV (strain Leningrad-16, MV-L16). To this end three groups of two cynomolgus macaques each were vaccinated via different routes with 10(3.8) TCID(50) MV-L16 vaccine: intramuscularly (i.m.), intraintestinally (i.i.) upon laparotomy and via enteric-coated tablets. Upon vaccination, MV-L16 could only be isolated from one of the i.m.-vaccinated monkeys and not from any of the other five. Both the i.m.-infected monkeys and one of the i.i.-infected monkeys developed a MV-specific serum antibody response. Also, MV-specific CD8(+) IFN gamma-producing T cells could be demonstrated in all three monkeys that had seroconverted. Upon challenge with wild-type MV 1 year after vaccination, only these three monkeys proved to be protected. These data do not support the viability of the concept of oral vaccination with LAVs.
Asunto(s)
Vacuna Antisarampión/administración & dosificación , Administración Oral , Animales , Anticuerpos Antivirales/biosíntesis , Humanos , Inmunoglobulina M/sangre , Inyecciones , Inyecciones Intramusculares , Intestino Delgado , Macaca fascicularis , Sarampión/inmunología , Sarampión/prevención & control , Virus del Sarampión/inmunología , Virus del Sarampión/aislamiento & purificación , Virus del Sarampión/patogenicidad , Pruebas de Neutralización , Linfocitos T/inmunología , Comprimidos Recubiertos , Vacunas Atenuadas/administración & dosificaciónRESUMEN
Quil A-based candidate measles vaccines have been shown to be immunogenic and protective in cotton rats and macaques. Here we studied the longevity of protective VN antibody levels induced in macaques with one dose of measles virus (MV) iscom. Inactivated MV adjuvanted with iscom-matrix or with purified Quillaja saponin QA-22 were also tested. All animals developed high levels of VN antibody and MV-specific IFNgamma-producing cells. Especially the high VN antibody levels induced by the latter two preparations showed virtually no decrease during the 2-year follow-up. These highly promising candidate MV vaccines should now be tested in infant macaques in the presence or absence of passively transferred and/or maternally derived VN antibodies. In addition, the immunopathological safety of the constructs should be evaluated in the atypical measles model in rhesus macaques.
Asunto(s)
Anticuerpos Antivirales/inmunología , Vacuna Antisarampión/inmunología , Saponinas/química , Adyuvantes Inmunológicos/química , Animales , Anticuerpos Antivirales/fisiología , Activación de Linfocitos , Sarampión/inmunología , Sarampión/prevención & control , Virus del Sarampión/inmunología , Saponinas de Quillaja , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Virus Vaccinia , Proteínas Virales de Fusión/genética , Proteínas Virales de Fusión/inmunologíaRESUMEN
Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly. RSV vaccine development has been hampered by results of clinical trials in the 1960s, when formalin-inactivated whole-RSV preparations adjuvated with alum (FI-RSV) were found to predispose infants for enhanced disease following subsequent natural RSV infection. We have reproduced this apparently immunopathological phenomenon in infant cynomolgus macaques and identified immunological and pathological correlates. Vaccination with FI-RSV induced specific virus-neutralizing antibody responses accompanied by strong lymphoproliferative responses. The vaccine-induced RSV-specific T cells predominantly produced the Th2 cytokines interleukin-13 (IL-13) and IL-5. Intratracheal challenge with a macaque-adapted wild-type RSV 3 months after the third vaccination elicited a hypersensitivity response associated with lung eosinophilia. The challenge resulted in a rapid boosting of IL-13-producing T cells in the FI-RSV-vaccinated animals but not in the FI-measles virus-vaccinated control animals. Two out of seven FI-RSV-vaccinated animals died 12 days after RSV challenge with pulmonary hyperinflation. Surprisingly, the lungs of these two animals did not show overt inflammatory lesions. However, upon vaccination the animals had shown the strongest lymphoproliferative responses associated with the most pronounced Th2 phenotype within their group. We hypothesize that an IL-13-associated asthma-like mechanism resulted in airway hyperreactivity in these animals. This nonhuman primate model will be an important tool to assess the safety of nonreplicating candidate RSV vaccines.